Thia-epothilone derivatives for the treatment of cancer

1. A compound of Formula (I)

wherein

A is a group of formula (II):

wherein Q is sulphur or oxygen, z is CH, and R 6 is CH 3 , CH 2 OH or CH 2 NH 2 ,

U is hydrogen,

G-E is selected from the following groups,

wherein R′ is methyl,

R 1 is C 1 -C 4 -alkyl-,

L-V-W is a group of formula CH═CH—CH, CH 2 —CH 2 —CH or CH 2 —CH═C, wherein the double bonds may be cis or trans isomers,

n is 0 or 2,

X is oxygen or NH; and

R 3 and R 4 are each methyl,

or a pharmacologically acceptable salt thereof.

2. A method for treating a patient suffering from or susceptible to breast cancer or epidermoid cancer, comprising administering to the patient a compound of claim 1 .

3. The method of claim 2 wherein the patient is identified as suffering from breast cancer or epidermoid cancer and selected for treatment for breast cancer or epidermoid cancer, and the compound is administered to the identified and selected patient.

4. A compound of claim 1 , wherein X is oxygen or NH.

5. A compound of claim 1 , wherein R 1 is methyl, ethyl or propyl.

6. A compound of claim 1 , wherein R 3 and R 4 are methyl groups.

7. A compound of claim 1 wherein A is

8. A pharmaceutical composition comprising a compound of claim 1 or a pharmacologically acceptable salt-thereof.

9. The pharmaceutical composition of claim 8 , further comprising one or more carriers, adjuvants, diluents or mixtures thereof.

10. A method for treating a patient suffering from or susceptible to ovarian cancer, lung cancer, prostate cancer, cervix carcinoma, cancer of the bladder or leukemia, comprising administering to the patient a compound of claim 1 .